Cere­nion secures over EUR 4.3 Mil­lion to accel­er­ate Euro­pean expan­sion

Cere­nion’s invest­ment round, orga­nized togeth­er with Springvest, was suc­cess­ful­ly com­plet­ed, attract­ing total invest­ments of EUR 4.359 mil­lion.

The fund­ing will sup­port Cerenion’s next phase of inter­na­tion­al growth and accel­er­ate the com­mer­cial expan­sion of C‑Trend® EEG Sta­tion across Europe. The com­pa­ny will use the pro­ceeds from the share issue to strength­en its com­mer­cial oper­a­tions, expand inter­na­tion­al dis­trib­u­tor part­ner­ships, and sup­port the grow­ing adop­tion of its EEG mon­i­tor­ing solu­tions in acute care envi­ron­ments.

Fol­low­ing MDR cer­ti­fi­ca­tion of the C‑Trend EEG Soft­ware and the com­mer­cial roll­out of the C‑Trend EEG Sta­tion, Cere­nion has strength­ened its posi­tion as a next-gen­er­a­tion brain-mon­i­tor­ing com­pa­ny focused on mak­ing con­tin­u­ous EEG mon­i­tor­ing eas­i­er and more acces­si­ble in acute health­care.

“We are extreme­ly grate­ful for the strong trust shown by both new and exist­ing investors,” says Dr. Juk­ka Kor­te­lainen, CEO and Co-founder of Cere­nion. “We under­stand that trust must be earned through long-term com­mit­ment, clin­i­cal cred­i­bil­i­ty, and high-qual­i­ty exe­cu­tion. We are ful­ly com­mit­ted to being wor­thy of the con­fi­dence placed in us. I also want to thank Springvest for their excel­lent work in orga­niz­ing the invest­ment round.”

Cere­nion pro­vides AI-assist­ed quan­ti­ta­tive EEG solu­tions designed to sup­port clin­i­cal deci­sion-mak­ing and improve access to con­tin­u­ous EEG mon­i­tor­ing in acute health­care.

Source (text and image): Cere­nion